SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is currently a focal point for investors debating the stock's future amid intense technical volatility and mixed signals regarding its long-term growth versus aggressive share dilution. While some community members highlight its expanding backlog, acquisition strategy, and defense sector partnerships, others are concerned by repeated price pullbacks and are closely monitoring the company's ability to capitalize on its recent strategic positioning.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is currently trending as investors debate the impact of its manufacturing joint venture with Toyota, with the community split between those viewing the partnership as a scaling moat and those concerned by ongoing stock volatility and dilution. Bulls emphasize the firm's progress in FAA flight testing and infrastructure development, while bears continue to highlight high cash burn and the speculative nature of the eVTOL industry.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the following segments: Square and Cash App. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Block Inc. is surging following a major restructuring plan that includes cutting 40% of its workforce as the company pivots toward an AI-native operational model. The community is actively debating the implications of using AI to drive margin expansion versus the potential long-term risks of mass layoffs and reduced human capital.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant momentum and volatility as investors react to positive FDA briefing documents regarding its mRNA flu vaccine candidate ahead of a key advisory committee vote. The community is actively debating the stock's long-term growth potential through its expanding oncology and rare disease pipeline, while also tracking high short interest that has fueled speculation of a potential short squeeze.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as investors monitor the commercial launch of NEREUS for motion sickness and engage in active speculation regarding potential buyout interest from major pharmaceutical players. While the community remains focused on the company's pipeline developments and GLP-1 adjunct opportunities, ongoing discussions are fueled by frustration over persistent price volatility and the company's aggressive regulatory strategy.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is experiencing significant volatility and heavy volume as traders debate the company's pivot toward becoming an AI infrastructure backbone through its Private Connectivity Fabric and recent strategic acquisitions. While bulls point to massive hyperscaler deal potential and a critical fiber footprint as long-term catalysts, the stock faces intense selling pressure from institutional shorting and concerns regarding balance sheet constraints and legacy business decline.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing heightened investor volatility driven by intense competition from emerging prediction markets and ongoing debates over how these new event-based betting platforms impact its core sportsbook business. While community discourse remains polarized between long-term bulls highlighting robust revenue growth and record-breaking engagement and bearish traders concerned about institutional sell-offs and competitive threats, the stock is actively trending due to these conflicting narratives and shifting regulatory expectations.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is facing significant selling pressure as investors react to management's conservative outlook on its Watchman franchise, overshadowing the company's broader growth potential and ongoing share repurchase program. The stock is currently hitting multi-year lows, sparking intense debate among retail traders regarding whether this represents a capitulation event and a buying opportunity or a deeper issue with management's communication.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio Inc. (NUVB) is drawing significant market attention as it transitions into a commercial-stage oncology company, with community focus centering on the commercial launch of its flagship drug, Ibtrozi, and strategic pipeline developments. Investors are actively debating the company's long-term valuation in light of recent financing moves and persistent buyout speculation, while closely monitoring how the firm's best-in-class pipeline candidates compete within the evolving oncology landscape.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is attracting significant attention as investors rotate toward defensive healthcare plays, bolstered by strong performance in its core immunology portfolio and high-profile strategic acquisitions. The community is actively discussing the company's long-term pipeline strength and dividend stability in a choppy market environment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug

KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.

Why Kymera Therapeutics Stock Popped This Week

Key PointsIt completed the enrollment phase of a Phase 2b study of its leading drug candidate...

Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study

KYMR stock soars 17% as investor optimism was lifted following early enrollment completion in mid-stage AD study, moving KT-621 top-line data to year-end 2026.

Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?

Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline

Equity

Kymera said that it finished enrolling patients nearly six months ahead of schedule in a mid-stage trial for KT-621.


Stocks making the biggest moves midday: BlackBerry, Kymera Therapeutics, Apple, Wendy's & more

These are the stocks posting the largest moves midday...

Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?

Kymera Therapeutics (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study

Kymera shares climb after patient dosing begins in a phase I KT-485 study, triggering a $20 million milestone payment from Sanofi.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

Canaccord Genuity Group Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)

Canaccord Genuity Group started coverage on Kymera Therapeutics in a report on Wednesday. They issued a 'buy' rating and a $106.00 target price for the company...

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

Kymera Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.73	--	--	N/A
Q1 '26	-$0.88	-$0.71	19.37%	BEAT
Q4 '25	-$0.78	-$0.97	-23.78%	MISSED
Q3 '25	-$0.76	-$0.94	-23.44%	MISSED
Q2 '25	-$0.81	-$0.95	-17.28%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

KYMRKymera Therapeutics Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest KYMR News